Clinical Trial Update: Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating donor alloantigen reactive Tregs (darTregs) for reducing calcineurin inhibitor use in liver transplant recipients and their l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant
• Liver Transplant Rejection Risk Mitigation

Drugs mentioned

• darTregs (donor alloantigen reactive Tregs)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-09